Approval is supported by phase 3 INShore trial data demonstrating 95% sustained complete remission at 52 weeks with obinutuzumab compared with 73% with MMF.
The intravenous immune globulin replacement therapy is currently being evaluated in a phase 3 clinical trial assessing motor function and mobility in adult patients with stiff person syndrome.
The FDA has accepted and granted Priority Review to an application for lower doses of leniolisib to treat younger children with activated phosphoinositide 3-kinase delta syndrome.
HealthDay News — Nutritional deficiencies are a common and underrecognized risk among pediatric patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment, according to a study ...
Routine FDA testing found patulin above safety limits in Wholesome Pantry jars sold at ShopRite and four other chains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results